Drug-induced liver injury (DILI) occurrence is a major concern for pharmaceutical companies because it can lead to drug withdrawal from the market being imposed by an agency (Food and Drug Administration \[FDA\] or European Medicines *Agency* \[EMA\]) after a careful risk-benefit assessment, or during phase II or III clinical trials by consensus or by company decision. Actually, the worst scenario involves a postmarketing recall combining serious patient health and company damage, a major loss of income, lawsuits stretching over years, loss of credibility, and deteriorated image in media and medical community. Over a thousand drugs described in the modern pharmacopoeia can induce liver damage with different clinical presentations ([@CIT0004]; [@CIT0024]). Most cases of DILI are benign, accompanied by slight (or moderate) alterations of plasma parameters such as transaminases and bilirubin, and reversible upon treatment cessation. However, with some hepatotoxic drugs and in some patients, DILI may trigger acute liver failure requiring liver transplantation, or even leading to a fatal outcome ([@CIT0005]).

DILI is classically considered as either intrinsic or idiosyncratic. Whereas intrinsic DILI is usually dose-related and generally discovered during animal toxicity studies, idiosyncratic DILI is less predictable. Indeed, idiosyncratic hepatotoxicity occurs in some individuals with different genetic and metabolic predispositions, or in individuals exposed to other environmental factors ([@CIT0001]). It was reported that idiosyncratic DILI represents around 13% of acute liver failure cases in the United States ([@CIT0037]). However, because drugs inducing intrinsic hepatotoxicity during clinical development rarely reach the market, most cases of DILI can be considered as idiosyncratic ([@CIT0039]; [@CIT0043]). Importantly, both types of DILI can result from mitochondrial toxicity.

Indeed, mitochondrial dysfunction is considered as a key mechanism of DILI ([@CIT0001]; [@CIT0023]; [@CIT0039]; [@CIT0042]), although chemicals can cause hepatotoxicity through other pathways, such as the generation of reactive metabolites and specific immune reactions ([@CIT0027]; [@CIT0042]). All these initial events can have different deleterious consequences for the hepatocytes, thus leading to hepatic cytolysis. Importantly, drug-induced mitochondrial dysfunction may be elicited by a parent drug and/or by reactive metabolites generated through cytochrome P450 (CYP)-mediated metabolism ([@CIT0001]; [@CIT0023]; [@CIT0031]). Moreover, it is noteworthy that mitochondrial dysfunction is a generic term including alteration of different metabolic pathways and damage to mitochondrial components. For instance, drugs can (1) impair mitochondrial fatty acid oxidation, electron transfer within the mitochondrial respiratory chain, and the oxidative phosphorylation (OXPHOS) process; (2) deplete the mitochondrial genome by inhibiting the mitochondrial DNA (mtDNA) polymerase γ and/or induce oxidative damage to the mtDNA; and (3) trigger mitochondrial membrane permeabilization, thus inducing the release of mitochondrial proapoptotic proteins into the cytoplasm ([@CIT0001]; [@CIT0013]; [@CIT0023]; [@CIT0027]; [@CIT0039]; [@CIT0042]). In addition, drug-induced blockade of the mitochondrial respiratory chain results in overproduction of reactive oxygen species and lipid peroxidation ([@CIT0001]; [@CIT0002]; [@CIT0039]). Importantly, drug-induced mitochondrial dysfunction can be responsible for cytolytic hepatitis, microvesicular steatosis (Reye-like syndrome), steatohepatitis, liver failure, and even cirrhosis ([@CIT0001]; [@CIT0023]; [@CIT0039]). Drugs that can induce idiosyncratic DILI through mitochondrial toxicity are, for instance, valproic acid, troglitazone, and antiretroviral drugs such as stavudine and zidovudine ([@CIT0006]; [@CIT0023]; [@CIT0045]). Finally, it should be stressed that drug-induced mitochondrial toxicity can also involve extrahepatic tissues such as muscles, heart, pancreas, neurons, or kidney, thus eliciting reports on myopathy, rhabdomyolysis, pancreatitis, peripheral neuropathy, or renal dysfunction among others ([@CIT0012]; [@CIT0014]; [@CIT0017]; [@CIT0025]; [@CIT0044]).

Bearing in mind the serious consequences for patients and pharmaceutical industry, drug-induced mitochondrial dysfunction should be detected early, ideally during screening of potential drug candidates. The development of high-throughput *in vitro* screening techniques could represent a major breakthrough for a rapid selection of safer compounds ([@CIT0001]; [@CIT0002]; [@CIT0012]; [@CIT0014]; [@CIT0017]; [@CIT0023]; [@CIT0031]; [@CIT0039]). Hence, the main objective of this study was to determine whether DILI could be predicted using a combination of high-throughput *in vitro* screening tests performed on isolated mouse liver mitochondria. To this end, we selected 87 compounds documented for inducing DILI in human and 37 compounds without known clinical hepatotoxicity based on the updated "Hepatox" database (<http://hepatoweb.com/hepatox.php>).

MATERIALS AND METHODS {#s1}
=====================

*Reagents and compounds.* Oligomycin A, rotenone, *m*-chlorocarbonylcyanide phenylhydrazone (mClCCP), alamethicin, and other chemicals were purchased either from Sigma Aldrich (Saint-Quentin-Fallavier, France) or from Santa Cruz Biotechnology (Heidelberg, Germany). Cyclosporin A (CsA) was purchased from Tebu Bio SA (Le Perray-en-Yvelines, France).

*Purification of mouse liver mitochondria.* Liver mitochondria from 6-week-old BALB/cByf female mice (Charles River, Saint-Germain-sur-L'arbresle, France) were isolated and purified by isopycnic density-gradient centrifugation in Percoll, as previously described ([@CIT0009]; [@CIT0026]), allowing pure and stable mitochondrial preparations. In previous experiments, we found that parameters measured from mitochondria isolated from female mice showed less interindividual variability than mitochondria from male mice, in particular in response to chemicals (Brenner and Borgne-Sanchez, unpublished data).

*Assessment of large amplitude swelling and ΔΨ* ~*m*~. Mitochondrial swelling and mitochondrial transmembrane potential (ΔΨ~m~) were evaluated as described previously ([@CIT0009]) in presence of succinate and rotenone. Calcium (CaCl~2~; 50µM) and mCICCP (50µM) were used as the 100% baseline for swelling and loss of ΔΨ~m~, respectively. Effective concentration at 20% of the maximal effect (EC~20~) for these parameters were the drug concentrations leading to 20% of the maximal swelling and 20% of the maximal loss of ΔΨ~m~ after a 30-min incubation, respectively.

*Determination of cytochrome* c *release.* Cytochrome *c* release was evaluated as described previously ([@CIT0009]) using an ELISA kit (R&D Systems, France). Treatment with 20 µg/ml alamethicin, a peptide able to form channels in membranes, was used as the 100% baseline. EC~20~ for this parameter was the drug concentration inducing 20% of the maximal cytochrome *c* release after a 30-min incubation.

*Measurement of oxygen consumption.* Oxygen consumption was monitored as previously described ([@CIT0049]), with some modifications. Briefly, isolated mitochondria (100 µg proteins) were incubated with drug in buffer containing 250mM sucrose, 30mM K~2~HPO~4~, 1mM EGTA, 5mM MgCl~2~, 15mM KCl, and 1mg/ml bovine serum albumin supplemented with respiratory substrates and 50nM MitoXpress, an oxygen-sensitive phosphorescent dye (LUXCEL, Cork, Ireland). Mitochondrial respiration was measured in the presence of 1.65mM ADP (state 3 of mitochondrial respiration) and with substrates for complex I (5mM malate and 12.5mM glutamate) or complex II (25mM succinate). Rotenone (2µM), a specific inhibitor of complex I, was also added for the assessment of mitochondrial respiration with succinate. Oxygen consumption was then measured in real time for 60min at 37°C in 96-well plates using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Rotenone (2µM) and oligomycin A (1µM) were used as 100% baseline for complex I and complex II inhibition, respectively. The areas under curve were used for calculations. To calculate the activation, the untreated mitochondria were taken as 0% activation. EC~20~ was the drug concentration causing 20% of the maximal inhibition or activation of oxygen consumption. For some fluorescent or colored compounds (*n* = 17) interfering with the MitoXpress probe, oxygen consumption through complex I and complex II was measured using a Clark electrode as described previously ([@CIT0009]).

*Selection of parameters to detect drug-induced mitochondrial toxicity.* Drugs can induce mitochondrial toxicity by altering mitochondrial membrane permeability and/or inhibiting the respiratory chain ([@CIT0001]; [@CIT0023]; [@CIT0039]). These events can be rapidly studied on isolated mouse liver mitochondria by assessing the mitochondrial swelling, loss of ΔΨ~m~, cytochrome *c* release, and oxygen consumption (i.e., respiration). Swelling and loss of ΔΨ~m~ were comonitored by real-time spectrofluorimetry (Figs. 1A and 1B). Calcium (Ca^2+^) was used as positive control inducing a massive mitochondrial swelling ([Fig. 1A](#F1){ref-type="fig"}, left) and loss of ΔΨ~m~ ([Fig. 1B](#F1){ref-type="fig"}, left) through mitochondrial permeability transition pore (mPTP) opening with subsequent cytochrome *c* release ([Fig. 1C](#F1){ref-type="fig"}, left). Importantly, the specific mPTP inhibitor CsA inhibited the Ca^2+^-induced swelling ([Fig. 1A](#F1){ref-type="fig"}, right), loss of ΔΨ~m~ ([Fig. 1B](#F1){ref-type="fig"}, right), and cytochrome *c* release ([Fig. 1C](#F1){ref-type="fig"}, right). The OXPHOS uncoupler mClCCP was used to decrease the ΔΨ~m~ in a mPTP-independent manner ([Fig. 1B](#F1){ref-type="fig"}, right). Alamethicin was chosen as a positive control inducing a massive cytochrome *c* release ([Fig. 1C](#F1){ref-type="fig"}). Besides mitochondrial membrane integrity, we also assessed the oxygen consumption with respiratory substrates oxidized by complex I (malate + glutamate) ([Fig. 1D](#F1){ref-type="fig"}) or complex II (succinate) ([Fig. 1E](#F1){ref-type="fig"}). The oxygen sensitive probe MitoXpress was used for most compounds for a rapid screening by spectrofluorimetry ([@CIT0049]).

![Selected parameters used to detect mitochondrial alterations. (A) Mitochondrial swelling. Left panel: mitochondria isolated from mouse liver were untreated (◆) or treated with increasing Ca^2+^ concentrations before evaluation of mitochondrial swelling (▲200, ◼100, ◼50, •25, •12.5, and ◼6.25µM). Right panel: massive mitochondrial swelling induced by 50µM Ca^2+^ (◼) was taken as 100% baseline. Preincubation of mitochondria with 10µM CsA (•) fully inhibited mitochondrial swelling induced by 12.5µM Ca^2+^ (•), thus giving a curve similar to untreated mitochondria (◆). (B) Loss of ΔΨ~m~. Left panel: loss of ΔΨ~m~ was simultaneously measured in real time in presence of increasing Ca^2+^ concentrations (same symbols as left panel of [Fig. 1A](#F1){ref-type="fig"}). Right panel: collapse of ΔΨ~m~ induced by 50µM mClCCP (◼) was taken as 100% baseline. Preincubation with 10µM CsA (•) fully inhibited the collapse of ΔΨ~m~ induced by 12.5µM Ca^2+^ (•), thus giving a curve similar to untreated mitochondria (◆). (C) Cytochrome *c* release. Left panel: supernatants of Ca^2+^- and alamethicin-treated mitochondria were subjected to ELISA assays to assess cytochrome *c* release. Massive cytochrome *c* release obtained with 20 µg/ml alamethicin was used as 100% baseline. Right panel: preincubation with 10µM CsA almost fully inhibited the cytochrome *c* release induced by 25µM Ca^2+^. (D) Mitochondrial respiration through complex I. Oxygen consumption in the presence of malate, glutamate, and ADP was measured without (◆) or with rotenone (◼2, ▲1, ◼0.5, •0.25, •0.125, and ◼0.062µM). The massive oxygen consumption inhibition caused by 2µM rotenone was taken as 100% baseline. (E) Mitochondrial respiration through complex II. Oxygen consumption in the presence of succinate, ADP, and rotenone was measured without (◆) or with oligomycin A (◼1, ▲0.5, ◼0.25, •0.125, •0.062, and ◼0.031µM). The massive oxygen consumption inhibition caused by 1µM oligomycin A was taken as 100% baseline.](toxsci_kfs197_f0001){#F1}

*Statistical analysis.* In this study, data related to mitochondrial toxicity were only those obtained from our multiparametric assay, and thus data from the literature were not considered for statistical analysis. The relationship between mitochondriotoxicity (yes/no) and hepatotoxicity (yes/no) was assessed using a χ^2^-test. Sensitivity, specificity, and predictive values of mitochondriotoxicity in term of hepatotoxicity were calculated as below:

![](toxsci_kfs197_kfs01)

RESULTS {#s2}
=======

Multiparametric Screening of 124 Compounds, Mainly Drugs, on Isolated Mouse Liver Mitochondria {#s3}
----------------------------------------------------------------------------------------------

We measured the ability of numerous hepatotoxic (*n* = 87) and nonhepatotoxic (*n* = 37) compounds to induce mitochondrial toxicity ([Table 1](#T1){ref-type="table"}). Compounds able to induce liver injury were selected within the library created by [@CIT0004] and the corresponding updated "Hepatox" database (<http://hepatoweb.com/hepatox.php>). These 124 compounds were all tested for their ability to induce swelling, loss of ΔΨ~m~, cytochrome *c* release, or an inhibition of the succinate-driven state 3 oxygen consumption. Compounds not altering these four parameters were then evaluated for their ability to inhibit oxygen consumption in the presence of malate and glutamate. For all these parameters, EC~20~ were determined in comparison with the 100% baseline obtained with their respective positive controls. It is noteworthy that some compounds (e.g., carbamazepine, erlotinib, lidocaine, saquinavir, spectinomycin, and zidovudine) increased oxygen consumption with malate/glutamate and/or succinate. Nevertheless, these compounds were considered as toxic for mitochondria. Indeed, enhanced oxygen consumption often reflects an increased mitochondrial entry of protons, which can be elicited by OXPHOS uncoupling, or by a global loss of inner mitochondrial membrane integrity ([@CIT0001]; [@CIT0013]; [@CIT0023]).

###### 

Effects of the Compounds on Each Parameter of Mitochondrial Toxicity

  Compound               Therapeutic class           Route of administration   Swelling   ΔΨ~m~ loss   Cyto *c*   O~2~ cons CII   O~2~ cons CI   *C* ~max~ µM
  ---------------------- --------------------------- ------------------------- ---------- ------------ ---------- --------------- -------------- --------------
  Acetaminophen          Analgesic                   IV, PO, R                 \> 200     \> 200       \> 400     348.5           \> 400         130
  Acetylsalicylic acid   NSAID                       PO                        \> 800     335.5        \> 200     \> 800          149.8          1650
  Alpidem                Anxiolitic                  PO                        ND         83.7         394.7      25.6            29.6           0.3
  Amantadine             Antiviral                   PO                        \> 800     261.2        \> 400     \> 400          \> 400         1.7
  Ambroxol               Expectorant                 PO                        \> 400     \> 200       \> 400     \> 400          \> 200         0.48
  Amiodarone             Antiarythmic                IV, PO                    ND         2.6          \< 50      45.92           ND             0.81
  Amoxicillin            Antibiotic                  IM, IV, PO                \> 400     \> 400       \> 400     90.8\*          188.8\*        14.1
  Ampicillin             Antibiotic                  IM, IV                    \> 400     \> 400       \> 400     \> 400          161.2\*        8.42
  Antipyrine             NSAID                       A, PO                     \> 400     300.0        \> 400     \> 400          \> 400         92.5
  Arsenic trioxide       Anticancer                  IV                        \> 200     237.9        \> 200     \< 50           0.9            0.17
  Atorvastatin           Hypolipidemic               PO                        5.6        4.3          \< 50      44.5            ND             0.06
  Biotin                 Nutritive agent             IM, IV, PO                \> 400     \> 400       \> 400     \> 400          \> 400         \< 1
  Bisacodyl              Antihypertensive            PO, R                     \> 400     312.4        \> 400     50.9            52.5           0.15
  β-Estradiol            Hormone                     C, IM, PO, V              ND         \> 200       \> 200     \> 200          \> 200         0.0006
  Bupivacaine            Local anesthetic            IS                        \> 800     258.2        \> 800     60.6            \> 800         0.7
  Busulfan               Anticancer                  IV, PO                    \> 800     483.1        \> 400     169.8           ND             4.9
  Butein                 Anticancer                  IP                        \> 200     \> 200       \> 200     29.6            ND             ND
  Caffeine               Analgesic                   PO                        \> 400     \> 400       \> 400     \> 400          \> 400         42
  Capsaicin              Topical analgesic           C                         \> 200     275.0        \> 200     15.0            15.7           0.06
  Carbamazepine          Anticonvulsivant            PO                        \> 200     66.9         \> 400     53.4            170.8\*        6.43
  Cefixime               Antibiotic                  PO                        \> 400     \> 400       \> 400     41.8            216.8          7.29
  Chlorambucil           Anticancer                  PO                        \> 200     \> 200       \> 200     138.7           140.9          1.97
  Ciprofloxacin          Antibiotic                  IV, PO                    \> 400     \> 400       \> 400     195.0\*         ND             16
  Clodronate             Antihypercalcemic           IV, PO                    \> 400     \> 400       \> 400     \> 400          227.2          2.77
  Clotrimazole           Antifungal                  V                         ND         23.9         \> 800     2.9             ND             1.02
  Coumarin               Anticoagulant               C, PO                     \> 200     0.9          \> 100     ND              ND             1.25
  Curcumin               Phytotherapy                PO                        \> 200     \> 200       \> 200     \> 200          \> 200         1.75
  Dapsone                Antibiotic                  PO                        \> 400     \> 400       \> 400     \> 400          205.5          5.6
  Dasatinib              Anticancer                  PO                        127.0      20.8         167.7      200.4           42.8\*         0.23
  Daunorubicin           Anticancer                  IV                        \< 6.25    ND           47.2       12.8            10.9           78
  Dexamethasone          Glucocorticoid              A, O, PO                  \> 200     \> 200       \> 200     \> 200          \> 200         0.23
  Diazoxide              Antihypertensive            PO                        \> 200     \> 200       \> 200     4.9             ND             151.73
  Diclofenac             NSAID                       C, IM, PO                 \> 800     137.9        \> 200     9.1             29.8           4.2
  Diflunisal             NSAID                       IV, PO                    \> 200     17.9         \> 200     9.8             ND             495
  Dipyrone               Analgesic                   IV, PO                    \> 200     354.4        \> 200     136.0           107.3          34.5
  Disulfiram             Antialcoholism              PO                        \> 400     12.6         \> 400     \< 100          ND             5.4
  Doxorubicin            Anticancer                  PO                        85         8.9          23.3       15.9            ND             0.2
  D-penicillamine        Immunosuppressor            IV                        \> 400     \> 400       \> 400     \> 800          \> 800         53.62
  Econazole              Antifungal                  C, V                      30.5       13.3         298.7      4.2             ND             540
  Erlotinib              Anticancer                  PO                        ND         195.9        ND         328.8           17.4\*         13.79
  Erythromycin           Antibiotic                  C, IV, PO                 \> 400     \> 400       \> 400     293.7           27.9           11
  Ethyl paraben          Preservative                C, PO                     \> 400     297.5        \> 400     293.1           47.8           ND
  Folic acid             Vitamin                     IV, PO                    \> 800     276.2        \> 400     \> 400          213.0          3.4
  Fluconazole            Antifungal                  PO                        \> 400     512.7        \> 400     \> 400          186.6          21.94
  Flufenamic acid        NSAID                       PO                        \> 200     42.5         \> 200     1.7             ND             46
  Flutamide              Antiandrogen                PO                        \> 800     27.0         \> 400     ND              ND             6
  Gallic acid            Antioxidant                 PO                        \> 200     \> 200       \> 200     103.7           153.9          2
  Gefitinib              Anticancer                  PO                        63.6       9.6          50.5       269.6           ND             0.72
  Genistein              Anticancer                  PO                        \> 200     150.6        \> 200     81.3            ND             1.84
  Gentamicin             Antibiotic                  IM, IV, O                 \> 800     49.0         \> 200     \> 200          ND             13
  Glimepiride            Antidiabetic                PO                        ND         94.6         \> 800     16.6            ND             0.5
  Gossypol               Anticancer                  PO                        \> 10      1.0          \> 10      30.3            ND             1.99
  Hyperforin             Antidepressant              PO                        \> 10      0.1          \> 10      ND              ND             0.23
  Ibuprofen              NSAID                       C, PO                     \> 200     355.9        \> 200     170.1           132.1          250
  Imatinib               Anticancer                  PO                        ND         25.7         163.6      ND              ND             2.71
  Imipramine             Antidepressant              PO                        274.4      74.8         \> 400     75.5\*          18.3\*         0.6
  Indomethacin           NSAID                       O, PO, R                  \> 800     443.2        \> 200     25.2            ND             6
  Isoniazide             Antibiotic                  PO                        \> 800     504.6        \> 400     59.8            ND             40
  Ketoconazole           Antifungal                  C                         \> 400     243.0        \> 400     \> 400          2.9            7
  Lamivudine             Antiretroviral              PO                        \> 400     347.2        ND         160.7           317.4          17
  Lidocaine              Local anesthetic            A, B, O                   \> 800     339.5        \> 800     \> 400          188.2\*        36
  Lonidamine             Anticancer                  IV, PO                    660.0      138.1        \> 800     18.9            ND             23.6
  Lovastatin             Hypolipidemic               PO                        71.5       43.6         118.2      4.4             6.2            0.01
  Lumiracoxib            NSAID                       PO                        \> 200     148.8        \> 800     26.3            12.0           22.47
  Manganese chloride     Nutritive agent             IV, PO                    \> 800     \> 800       \> 800     \> 400          \> 400         0.053
  Mefenamic acid         NSAID                       PO                        \> 400     49.7         \> 200     10.1            ND             15.74
  Mercaptopurine         Anticancer                  PO                        \> 400     406.9        \> 400     130.8           131.8\*        1
  Metformin              Antidiabetic                PO                        \> 400     388.4        \> 800     \> 400          351.8          4.5
  Methimazole            Antithyroid                 PO                        \> 400     \> 400       ND         193.8           368.6          9.2
  Methyldopa             Antihypertensive            PO                        \> 400     \> 400       ND         \> 800          63.1           11
  Methyl paraben         Preservative                C, PO                     \> 200     \> 200       \> 200     \> 200          94.8           ND
  Mitomycin C            Antineoplastic antibiotic   IV                        ND         \> 200       \> 200     4.9             ND             7.1
  Mitoxantrone           Anticancer                  IV                        ND         7.00         \> 400     ND              ND             1.9
  Molsidomine            Antianginal                 PO                        \> 400     \> 400       \> 400     \> 200          \> 200         0.31
  Naloxone               Analgesic                   IV                        \> 400     298.7        \> 400     233\*           \> 400         0,00047
  Nelfinavir             Antiretroviral              PO                        ND         6.3          \> 200     \< 25           ND             6
  Nicergoline            Anti-ischemic               PO                        169.8      82.6         \> 200     57.0\*          42.7\*         0.0002
  Nicotine               Smoking deterrent           C, PO                     \> 400     \> 400       \> 400     \> 400          312            0.09
  Nifuroxazide           Antibiotic                  PO                        \> 400     388.2        \> 400     61.5            3.7            ND
  Nilotinib              Anticancer                  PO                        ND         11.5         \> 400     ND              71.4\*         3.6
  Nimesulide             NSAID                       PO                        \> 200     10.1         \> 200     \< 25           ND             15
  Nitrofurantoin         Antibiotic                  PO                        \> 800     442.5        \> 400     232.3           8.7            6
  Novobiocin             Antibiotic                  PO                        289.5      351.6        \> 400     88.2            173.5          1
  Oxybutynine            Spasmolytic                 PO                        302.8      178.3        \> 400     172.8           115.4          0.17
  Pargyline              Stimulant laxative          PO                        \> 400     243          \> 400     \> 400          206.8          0.3
  Perhexiline            Antianginal                 PO                        14.8       3.2          \< 25      88.4            87.7           0.28
  Phenylbutazone         NSAID                       C                         \> 400     140.2        ND         11.4            ND             438
  Phloroglucinol         Antispasmodic               IM, IV, PO                \> 800     \> 800       \> 400     \> 400          \> 400         ND
  Piroxicam              NSAID                       IM, PO                    \> 200     101.7        \> 200     224.5           6.6            5
  Pravastatin            Hypolipidemic               PO                        \> 200     \> 200       \> 200     5.0             ND             0.10
  Propyl paraben         Preservative                C, PO                     \> 800     162.8        \> 800     63.0            28.4           ND
  Propylthiouracil       Antithyroid                 PO                        \> 800     391.5        \> 400     66.9\*          15.8\*         42
  Pyrazinamide           Antibiotic                  PO                        \> 400     \> 400       \> 400     107.5           190.9          325
  Ranitidine             Antiulcer agent             IM, IV, PO                \> 400     368.1        ND         \> 400          97.3           3.99
  Resveratrol            Antiaging                   PO                        \> 200     395.4        \> 200     7.7             ND             0.18
  Riboflavin             Vitamin                     IV, PO                    672.3      ND           \> 400     264.6           182.8          0.0039
  Rifampicin             Anti-infectious             IV, PO                    \> 800     \> 800       \> 200     124.1           ND             9
  Ritonavir              Antiretroviral              PO                        ND         24.8         ND         35.5            ND             7.07
  Roxithromycin          Antibiotic                  PO                        310.0      244.8        \> 400     104.9           ND             13.14
  Saccharin              Sweetening agent            PO                        \> 400     \> 400       \> 400     \> 400          179.4          147.37
  Salicylic acid         NSAID                       C, O                      \> 400     304.3        \> 200     354.4           120.9          604.63
  Saquinavir             Antiretroviral              PO                        ND         10.3         \> 400     21.1\*          30.4\*         0.37
  Simvastatin            Hypolipidemic               PO                        173.2      76.5         \> 200     1.6             ND             0.02
  Sorafenib              Anticancer                  PO                        ND         0.5          \> 400     283.4           ND             5.60
  Spectinomycin          Antibiotic                  IM                        \> 400     \> 400       \> 400     185.9\*         118.2\*        322.97
  Streptomycin           Antibiotic                  IM, IV                    417.5      78.8         ND         \> 400          ND             52
  Sucrose                Antiasthenic                PO                        \> 800     \> 800       \> 800     \> 800          \> 800         ND
  Sulfamethoxazole       Antibiotic                  IV, PO                    \> 400     \> 400       \> 400     \> 400          \> 400         159.9
  Sulindac               NSAID                       PO                        \> 200     \> 200       \> 200     \> 400          35.6           19
  Sumatriptan            Antiheadaches               N, PO, SCI                \> 400     248.3        \> 400     \> 400          \> 400         0.04
  Sunitinib              Anticancer                  PO                        ND         23.2         ND         222.8           ND             70.8
  Tamoxifen              Anticancer                  PO                        9.0        2.9          7.7        ND              ND             0.40
  Taurine                Antiasthenic                IV                        \> 800     \> 800       \> 800     \> 800          \> 800         ND
  Terbinafine            Antifungal                  C, PO                     20.6       12.5         \> 50      ND              ND             4
  Ticlopidine            Antiplatelet                PO                        58.9       50.5         ND         ND              ND             7.06
  Tolcapone              Anti-Parkinson              PO                        \> 400     3.9          \> 400     ND              ND             27.81
  Tolfenamic acid        NSAID                       PO                        335.3      7.1          \> 200     3.7             ND             4.16
  Tramadol               Analgesic                   IV, PO                    \> 800     263.8        \> 400     \> 400          238.7\*        1.9
  Troglitazone           Antidiabetic                PO                        \> 200     3.4          \> 400     3.9             6.0            6.60
  Troxerutin             Antihemoroid                PO                        \> 400     \> 400       \> 400     39.3            170.5          0.004
  Valproic acid          Antiepileptic               IV                        \> 800     267.2        \> 800     \> 400          44.9           902
  Vinblastine            Anticancer                  IV                        185.7      25.7         \> 400     5.6             102.3\*        0.13
  Ximelagatran           Anticoagulant               PO                        \> 400     535.7        \> 800     85.6            341.8\*        0.45
  Zidovudine             Antiretroviral              IV, PO                    \> 200     416.1        \> 200     \> 800          242.0\*        4

*Note.* Selected compounds (*n* = 124) were tested for their ability to induce swelling, loss of ΔΨ~m~, cytochrome *c* release, and inhibition of mitochondrial respiration through complexes I and II. EC~20~ was calculated using GraphPad Prism 4. EC~20~ with an asterisk (\*) indicates drug-induced acceleration of oxygen consumption. Results are means of two to three independent experiments (SD \< 10%). The *C* ~max~ found in the literature (PubMed) or databases (Pharmapendium, RxList, and ToxNet) are indicated. For each compound the therapeutic class and the usual route of administration are indicated (data from the Vidal and DrugBank databases). A, auricular; B, buccal; C, cutaneous; IM, intramuscular; IP, intraperitoneal; IS, intraspinal; IV, intravenous; N, nasal; ND, not determined; O, ophthalmic; PO, per os; R, rectal; SCI, subcutaneous injection; V, vaginal.

Correlation Analysis Between Mitochondrial Toxicity and DILI in Human {#s4}
---------------------------------------------------------------------

Two different approaches were used to ascertain drug-induced mitochondrial toxicity ([Table 2](#T2){ref-type="table"}). In the first approach, a drug was considered as toxic for mitochondria if, for at least one of the five mitochondrial parameters, the EC~20~ was ≤ 100 × *C* ~max~ (maximal plasma concentration), a cutoff currently used for safety assessment in pharmaceutical industry ([@CIT0011]). Because *C* ~max~ was not available for several compounds selected in this study, we used a second approach for which a compound was considered as toxic for mitochondria if the EC~20~ was ≤ 200µM for at least one of the five mitochondrial parameters. We indicated for each hepatotoxicant ([Table 2A](#T2){ref-type="table"}) the proposed (or suspected) mechanisms of toxicity, if any, and whether DILI was detected in animals. For nonhepatotoxic compounds ([Table 2B](#T2){ref-type="table"}) the occurrence of other organ toxicities was reported.

###### 

Mitochondrial Toxicity of the 124 Selected Compounds

  ----------------------------------------------------------------------------------------------------------------
  Compound               Mitotox                     Known or suspected mechanism(s)   Animal hepatotox        
  ---------------------- --------------------------- --------------------------------- ----------------------- ---
  Acetaminophen          Y                           N                                 RM, OS, M               Y

  Acetylsalicylic acid   Y                           Y                                 OS, M, Apop              

  Alpidem                Y                           Y                                 RM, OS, M                

  Amiodarone             Y                           Y                                 OS, M, SL               N

  Amoxicillin            Y                           Y                                 OS                      N

  Ampicillin             Y                           Y                                 M                       Y

  Arsenic trioxide       Y                           Y                                 M, Apop                 N

  Atorvastatin           Y                           Y                                 IM, M, Apop             N

  Bupivacaine            Y                           Y                                 M, OS                   N

  Busulfan               Y                           Y                                 OS                      Y

  Carbamazepine          Y                           Y                                 RM, M                   Y

  Cefixime               Y                           Y                                                         Y

  Chlorambucil           Y                           Y                                 OS                       

  Ciprofloxacin          Y                           Y                                 OS                      N

  Clotrimazole           Y                           Y                                                         Y

  Coumarin               Y                           Y                                 RM, OS                   

  Dapsone                Y                           N                                 RM, OS                  N

  Dasatinib              Y                           Y                                                         N

  Daunorubicin           Y                           Y                                 OS                      Y

  Dexamethasone          N                           N                                 SL, M                   N

  Diclofenac             Y                           Y                                 RM, OS, M, Apop, IM     Y

  Diflunisal             Y                           Y                                 RM, M                   N

  Dipyrone               Y                           Y                                                          

  Disulfiram             Y                           Y                                 OS, M                   N

  Doxorubicin            Y                           Y                                 OS, Apop                N

  D-penicillamine                                    N                                 IM                      N

  Econazole              Y                           Y                                                         N

  Erlotinib              Y                           Y                                 RM                      Y

  Erythromycin           Y                           Y                                 IBST, RM                N

  Fluconazole            Y                           Y                                                         Y

  Flufenamic acid        Y                           Y                                 M                       N

  Flutamide              Y                           Y                                 RM, M                   N

  Gefitinib              Y                           Y                                 RM                      Y

  Gentamicin             Y                           Y                                 M, OS                   N

  Glimepiride            Y                           Y                                                         N

  Gossypol               Y                           Y                                 M                        

  Ibuprofen              Y                           Y                                 M                       N

  Imatinib               Y                           Y                                                         Y

  Imipramine             Y                           Y                                 RM, M                   N

  Indomethacin           Y                           Y                                 M                       N

  Isoniazid              Y                           Y                                 IM, RM, OS              N

  Ketoconazole           Y                           Y                                 RM, OS, M               N

  Lamivudine             Y                           Y                                 M                       N

  Lidocaine              Y                           Y                                 M                       N

  Lonidamine             Y                           Y                                 M, Apop                  

  Lovastatin             N                           Y                                 M                       N

  Lumiracoxib            Y                           Y                                 RM                       

  Mefenamic acid         Y                           Y                                 M                       N

  Mercaptopurine         N                           Y                                 OS, M, DNA Syn          N

  Metformin              Y                           N                                 M                       Y

  Methimazole            Y                           Y                                 RM, OS                  N

  Methyldopa             Y                           Y                                 IM, RM                  N

  Mitomycin C            Y                           Y                                 RM, OS, DNA Syn         N

  Mitoxantrone           Y                           Y                                 RM, DNA Syn             N

  Nelfinavir             Y                           Y                                 SL, OS                  Y

  Nimesulide             Y                           Y                                 M, RM, OS               N

  Nitrofurantoin         Y                           Y                                 IM, OS, M               N

  Novobiocin             Y                           Y                                 DNA Syn, M              N

  Perhexiline            Y                           Y                                 M                       N

  Phenylbutazone         Y                           Y                                 M                       N

  Piroxicam              Y                           Y                                 M                       N

  Pravastatin            Y                           Y                                                         Y

  Propylthiouracil       Y                           Y                                 IM                      N

  Pyrazinamide           Y                           Y                                 OS                      N

  Ranitidine             Y                           Y                                                         N

  Rifampicin             Y                           Y                                 IBST, OS                Y

  Ritonavir              Y                           Y                                 Apop, SL                Y

  Roxithromycin          Y                           Y                                                         N

  Saccharin              Y                           Y                                                          

  Saquinavir             Y                           Y                                 SL                      N

  Simvastatin            Y                           Y                                 Apop, M                 N

  Sorafenib              Y                           Y                                 Apop                    N

  Spectinomycin          Y                           Y                                                          

  Streptomycin           Y                           Y                                 M                        

  Sulindac               Y                           Y                                 IBST, OS, M             N

  Sunitinib              Y                           Y                                 Apop                    N

  Tamoxifen              Y                           Y                                 M, RM, OS, SL           N

  Terbinafine            Y                           Y                                 RM                      Y

  Ticlopidine            Y                           Y                                 RM, IM                  Y

  Tolcapone              Y                           Y                                 M, RM                   N

  Tolfenamic acid        Y                           Y                                 M                        

  Tramadol               N                           N                                                         N

  Troglitazone           Y                           Y                                 RM, M, OS, IBST, Apop   Y

  Valproic acid          Y                           Y                                 M, RM                   N

  Vinblastine            Y                           Y                                 Apop                    N

  Ximelagatran           N                           Y                                 IM                      N

  Zidovudine             Y                           N                                 M                       N

  Compared to human      concordance:  94%  92%\                                                               
                         error rate:     6%    8%                                                              

  Compared to animal     concordance:  100%  90%\                                                              
                         error rate:     0%    10%                                                             
  ----------------------------------------------------------------------------------------------------------------

  ------------------------------------------------------------------------------------
  Compound             Mitotox 100 × C~max~   Mitotox 200µM   Other organ toxicity
  -------------------- ---------------------- --------------- ------------------------
  Amantadine           N                      N               Heart

  Ambroxol             N                      N                

  Antipyrine           Y                      N                

  Biotin               N                      N                

  Bisacodyl            N                      Y                

  β-Oestradiol         N                      N               Pancreas

  Butein                                      Y                

  Caffeine                                    N               Reproduction

  Capsaicin            N                      Y               Skin

  Clodronate           Y                      N               Gastro intestinal

  Curcumin             N                      N                

  Diazoxide            Y                      Y               Kidney, pancreas (\*)

  Ethyl paraben                               Y               Reproduction (\*)

  Folic acid           Y                      N               Gastro intestinal, CNS

  Gallic acid          Y                      Y                

  Genistein            Y                      Y               Reproduction

  Hyperforin           Y                      Y                

  Manganese chloride   N                      N                

  Methyl paraben                              Y               Reproduction (\*)

  Molsidomine          N                      N                

  Naloxone             N                      N               Heart

  Nicergoline          N                      Y                

  Nicotine             N                      N                

  Nifuroxazide                                Y               Pancreas

  Nilotinib            Y                      Y               Heart (\*)

  Oxybutynine          N                      Y               Brain

  Pargyline            N                      N                

  Phloroglucinol       N                      N                

  Propyl paraben                              Y               Reproduction (\*)

  Resveratrol          Y                      Y                

  Riboflavin           N                      Y                

  Salicylic acid       Y                      Y               Kidney

  Sucrose                                     N               Kidney

  Sulfamethoxazole                            N               Pancreas

  Sumatriptan          N                      N                

  Taurine                                     N                

  Troxerutin           N                      Y                

  Compared to human    concordance:  64%\     51%\             
                       error rate:    36%     49%             
  ------------------------------------------------------------------------------------

Note. The compounds are listed for their ability to induce (Y) or not (N) mitochondrial toxicity on isolated mouse liver mitochondria. Mitochondrial toxicity was ascertained by two approaches using a different cutoff (100 × Cmax or 200µM). Blanks mean that the mitochondrial toxicity related to Cmax could not have been determined because the Cmax value was not found in the literature or databases. (A) Hepatotoxicants in human according to [@CIT0004] and to the updated "Hepatox" database (http://hepatoweb.com/hepatox.php) with indication of known (or suspected) mechanisms of DILI and detection of hepatotoxicity in animals during preclinical studies. (B) Nonhepatotoxicants in human with indication of known toxicity to other organs where (\*) indicates known (or suspected) mitochondrial toxicity. Apop, apoptosis; DNA Syn, DNA synthesis; IBST, inhibition of bile salt transport; IM, immune-mediated; OS, oxidative stress; M, mitochondrial; RM, reactive metabolites; SL, stimulation of lipogenesis. Blanks are data not found in the databases or literature. The concordance and error rate between mitochondrial toxicity in our assay and human hepatotoxicity, and/or animal hepatototoxicity are indicated for each cutoff.

Using the first definition of mitochondrial toxicity (100 × *C* ~max~), only 114 compounds were taken into account ([Table 3A](#T3){ref-type="table"}). Interestingly, 81 of the 86 (94%) compounds able to induce DILI were found to be toxic for mitochondria, demonstrating a very high sensitivity. In contrast, 36% of the compounds not inducing DILI were found to be toxic for mitochondria. This difference was statistically significant and showed a significant relationship between mitochondrial toxicity and DILI (*p* \< 0.001). With the second approach (EC~20~ ≤ 200µM), all the 124 compounds were included ([Table 3B](#T3){ref-type="table"}) and 80 of the 87 (92%) compounds known to induce DILI were found to be toxic for mitochondria. However, 49% of the compounds not inducing DILI were found to be toxic for mitochondria. This difference was also statistically significant (*p* \< 0.001). Thus, by using two different definitions of mitochondrial liability, our study showed a highly significant relationship between toxicity on isolated mouse liver mitochondria and DILI in human.

###### 

Relationship Between Mitochondrial Toxicity and the Occurrence of DILI in Human

  -------------------------------------- --------------------------------- --------------------------------- ---------- -----------------
  A.                                                                                                                    

  Number (%) cutoff at 100 × *C* ~max~   Hepatotoxic compound              *p* value                                    

  Yes\                                   No\                                                                            
  *n* = 86                               *n* = 28                                                                       

  Mitochondriotoxic compound             Yes                               81 (94%)                          10 (36%)   \< 0.001 (χ^2^)

  No                                     5 (6%)                            18 (64%)                                     

                                                                           Predictive positive value: 89%\              
                                                                           Predictive negative value: 78%               

  B.                                                                                                                    

  Number (%) cutoff at 200µM             Hepatotoxic compound              *p* value                                    

  Yes\                                   No\                                                                            
  *n* = 87                               *n* = 37                                                                       

  Mitochondriotoxic compound             Yes                               80 (92%)                          18 (49%)   \< 0.001 (χ^2^)

  No                                     7 (8%)                            19 (51%)                                     

                                         Predictive positive value: 82%\                                                
                                         Predictive negative value: 73%                                                 
  -------------------------------------- --------------------------------- --------------------------------- ---------- -----------------

*Note.* Results of the χ^2^-test are reported with the two approaches used to establish mitochondrial toxicity induced by chemicals (A) ascertained with the 100 × *C* ~max~ cutoff and (B) ascertained with the 200µM cutoff. The *p* values are indicated for both conditions.

Our results indicated positive predictive values of 89 (81/91) and 82% (80/98) depending on the definition of mitochondrial toxicity ([Table 3](#T3){ref-type="table"}). Thus, any compound found to induce mitochondrial toxicity with our multiparametric assay would have a high probability for inducing DILI in human. We also calculated the negative predictive values that provided a reasonable threshold for correct clinical outcome with 78 (18/23) and 73% (19/26) depending on cutoff ([Table 3](#T3){ref-type="table"}). Specificity calculated as 64 or 51% depending on cutoff was modest, probably due to sample size and involvement of mitochondrial toxicity in other tissues. Interestingly, the false-negative group (i.e., nonmitochondriotoxic but hepatotoxic compounds) showed a low percentage (6 or 8%), which is encouraging in a screening assay contrary to the false-positive group (i.e., mitochondriotoxic but nonhepatotoxic compounds), which was much higher (36 or 49%).

Mitochondrial Toxicity of Compounds Already Known to Have Deleterious Effects on Mitochondria {#s5}
---------------------------------------------------------------------------------------------

In this study, we confirmed the mitochondrial toxicity of several chemicals mainly compounds for which such deleterious effect had already been demonstrated in different experimental models including rodent liver, primary cultured hepatocytes, and isolated mitochondria. This is, for instance, the case for alpidem, diclofenac, perhexiline maleate, and the highly debated troglitazone ([Table 1](#T1){ref-type="table"}; [Fig. 2](#F2){ref-type="fig"}).

![Mitochondrial toxicity of compounds already described to cause mitochondrial dysfunction. Isolated mouse liver mitochondria were untreated (◆) or treated with increasing concentrations (•, •, ◼, and ▲; range indicated on the graphs) of alpidem, diclofenac, perhexiline maleate, and troglitazone, or with positive controls (◼). Mitochondrial swelling, loss of ΔΨ~m~, cytochrome *c* release, and inhibition of oxygen consumption were thus assessed as described in Materials and Methods and [Figure 1](#F1){ref-type="fig"}.](toxsci_kfs197_f0002){#F2}

Alpidem was described to accelerate Ca^2+^-induced mPTP, uncouple OXPHOS, and selectively inhibit the respiratory complex I on isolated rat liver mitochondria ([@CIT0003]). In this study, this anxiolytic drug induced ΔΨ~m~ loss (EC~20~ = 83.7µM) and inhibited mitochondrial respiration for concentrations lower than 30µM, thus confirming a significant mitochondrial toxicity ([Table 1](#T1){ref-type="table"}; [Fig. 2A](#F2){ref-type="fig"}).

The nonsteroidal anti-inflammatory drug (NSAID), diclofenac, was shown to uncouple OXPHOS and induce mPTP opening on isolated rat mitochondria ([@CIT0030]). However, it is noteworthy that in this study, the assessment of mPTP opening was performed in the presence of Ca^2+^. Interestingly, we found that diclofenac was unable to induce mitochondrial swelling and cytochrome *c* release ([Table 1](#T1){ref-type="table"}; [Fig. 2B](#F2){ref-type="fig"}). Because our assay was carried out without Ca^2+^ pulse, these data suggest that diclofenac-induced mPTP opening occurs only when mitochondria are loaded with Ca^2+^. We demonstrated a clear inhibition of mitochondrial respiration through complex I (EC~20~ = 29.8µM) and complex II (EC~20~ = 9.1µM) with subsequent ΔΨ~m~ loss ([Table 1](#T1){ref-type="table"}; [Fig. 2B](#F2){ref-type="fig"}).

Several studies demonstrated that perhexiline maleate can induce mitochondrial dysfunction by different mechanisms, including OXPHOS uncoupling and inhibition of different enzymes involved in the mitochondrial respiratory chain and fatty acid oxidation ([@CIT0010]; [@CIT0021]). In our study, we confirmed that perhexiline maleate inhibited mitochondrial respiration when substrates gave their electrons to complexes I and II ([Table 1](#T1){ref-type="table"}; [Fig. 2C](#F2){ref-type="fig"}). Moreover, we discovered that perhexiline maleate induced mitochondrial swelling and cytochrome *c* release when very low concentrations were used ([Table 1](#T1){ref-type="table"}; [Fig. 2C](#F2){ref-type="fig"}), indicating that this antianginal drug can seriously disturb the mitochondrial membrane integrity.

The antidiabetic troglitazone has been reported to impair mitochondrial function by different mechanisms including mPTP opening and mtDNA damage ([@CIT0029]; [@CIT0034]; [@CIT0040]). However, as already mentioned for diclofenac, troglitazone-induced mPTP opening occurred in conditions of Ca^2+^ pulse ([@CIT0029]; [@CIT0034]). In this study, troglitazone was unable to trigger mitochondrial swelling and cytochrome *c* release ([Table 1](#T1){ref-type="table"}; [Fig. 2D](#F2){ref-type="fig"}), thus indicating that Ca^2+^ preloading is mandatory for troglitazone-induced mPTP opening. Nevertheless, we demonstrated that troglitazone inhibited mitochondrial respiration and induced ΔΨ~m~ loss when relatively low concentrations were used.

Mitochondrial Toxicity of Compounds Not Already Described to Induce Mitochondrial Dysfunction {#s6}
---------------------------------------------------------------------------------------------

This study allowed disclosing for the first time the mitochondrial toxicity of several drugs, such as lumiracoxib, nilotinib, and saquinavir ([Table 1](#T1){ref-type="table"}, [Fig. 3](#F3){ref-type="fig"}). Lumiracoxib and saquinavir were reported to cause liver injury (<http://hepatoweb.com/hepatox.php>), but the mechanisms underlying this hepatotoxicity had not been elucidated. Further investigations will be required to determine whether lumiracoxib- and saquinavir-induced impairment of the respiratory chain ([Table 1](#T1){ref-type="table"}, [Fig. 3](#F3){ref-type="fig"}) is indeed a key mechanism leading to liver injury. Although nilotinib hepatotoxicity has not been reported so far, this anticancer drug can induce moderate to severe cardiotoxicity ([@CIT0008]; [@CIT0036]).

![Mitochondrial toxicity of drugs with no previously reported mitochondrial liability. Isolated mouse liver mitochondria were untreated (◆) or treated with increasing concentrations (•, •, ◼, and ▲; range indicated on the graphs) of lumiracoxib, nilotinib, and saquinavir, or with positive controls (◼). Mitochondrial swelling, loss of ΔΨ~m~, cytochrome *c* release, and inhibition of oxygen consumption were thus assessed as described in Materials and Methods and [Figure 1](#F1){ref-type="fig"}.](toxsci_kfs197_f0003){#F3}

DISCUSSION {#s7}
==========

Drug-induced mitochondrial dysfunction can cause several types of hepatotoxicity including cytolytic hepatitis, microvesicular steatosis, steatohepatitis, liver failure, and even cirrhosis ([@CIT0001]; [@CIT0023]; [@CIT0039]). Furthermore, by inducing mitochondrial liability, compounds can also damage other tissues, such as skeletal muscles, heart, and pancreas. Thus, mitochondrial toxicity should be detected as early as possible during drug development, and ideally during the steps of hit selection and lead optimization. In this context, we showed that a combination of high-throughput *in vitro* screening tests performed on isolated mouse liver mitochondria allowed predicting whether a drug can be potentially harmful for the human liver. Indeed, we found a strong correlation between mitochondrial dysfunction as assessed with our selected tests and hepatotoxicity in humans independently of the type of liver damage. Furthermore, our study unveiled mitochondrial dysfunction with some hepatotoxic compounds for which such a liability had not been previously reported. Finally, these multiparametric assays clarified the mechanisms of mitochondrial toxicity for some compounds already known to induce mitochondrial dysfunction.

Preclinical toxicological tests should have high positive predictive value and sensitivity. In this study, as far as hepatotoxicity was concerned, the positive predictive value of our high-throughput *in vitro* screening tests was over 82%, whereas sensitivity was excellent (\> 92%). This indicates that the risk of DILI is expected to be high with new chemical entities affecting one (or several) of our selected mitochondrial parameters. From [Table 2A](#T2){ref-type="table"}, it appears that about 90% of human hepatotoxicants for which DILI was not detected during preclinical animal studies were found to be mitochondriotoxic in our assays. This was, for instance, the case for amiodarone, ketoconazole, and perhexiline, which showed mitochondrial toxicities using our testing platform. The concordance between mitochondrial toxicity measured in our assays and animal hepatotoxicity was 100% for the cutoff related to *C* ~max~ and 90% for the second cutoff. This study indicates that our platform could allow a better predictivity compared with classical animal studies used during preclinical development. This is in keeping with studies reporting that the concordance between hepatotoxicity detected in animal studies and that observed in clinical practice is around 50% ([@CIT0015]; [@CIT0035]). However, such valuable information on mitochondrial toxicity could not be used by itself as a decision-making go--no go strategy, but rather as a tool for ranking and prioritizing compounds in order to select safer candidates for subsequent *in vivo* preclinical safety investigations. Moreover, detection of mitochondrial toxicity with compounds of high pharmacological interest should prompt pharmaceutical companies to perform additional investigations using other *in vitro* studies or appropriate animal models ([@CIT0007]; [@CIT0023]). Hence, in order to select drug candidates, each pharmaceutical company should consider the potential medical benefits of the selected compounds and their toxicological profiles determined during preclinical safety studies. For instance, some nucleoside analogs, such as stavudine (d4T) and zidovudine (AZT), are currently key components of the highly active antiretroviral therapy despite the occurrence of mitochondrial toxicity in a significant number of treated patients ([@CIT0001]; [@CIT0013]; [@CIT0023]).

The negative predictive value of our screening tests ranged between 73 and 78%. Accordingly, the lack of mitochondrial dysfunction observed with a new chemical entity cannot exclude the possible occurrence of subsequent liver injury in human. A probable explanation is that mechanisms other than mitochondrial dysfunction can be involved in DILI, such as specific immune reactions and impairment of mitochondria-independent lipid homeostasis (e.g., reduced VLDL secretion or enhanced *de novo* lipogenesis) ([@CIT0001]; [@CIT0027]; [@CIT0042]).

If the false-negative group was very low (6 or 8%), the false-positive group was much higher (36 or 49%). This rather high level of false-positive results can be explained by the fact that drugs can be toxic to other organs through mitochondrial toxicity ([Table 2B](#T2){ref-type="table"}). Other reasons for detecting false positives could be attributed to the selected cutoff concentrations (which can be adjusted to the pharmacological efficient concentrations), or to the detection of transient and reversible mitochondrial dysfunction that will have no detrimental effect on liver integrity.

Because our screening tests are performed on isolated mitochondria, it can be argued that they cannot detect mitochondrial toxicity induced by CYP-generated reactive metabolite(s). However, it is noteworthy that [@CIT0020] recently showed that a short incubation of isolated mitochondria with sumatriptan was sufficient to metabolize 30% of the compound. This is most probably due to the presence of some CYPs within mitochondria such as CYP2E1 ([@CIT0041]), CYP1A2, and CYP2D6 (Buron and Borgne-Sanchez, unpublished data). Thus, it is possible that reactive metabolite(s) could be generated with some drugs during the assay and that the observed mitochondrial dysfunction resulted from the parent drug or from a CYP-generated toxic metabolite. It is noteworthy that, in this study, one-third of the investigated chemicals (with identified mechanism of action) are metabolized into reactive metabolites ([Table 2A](#T2){ref-type="table"}). Interestingly, all these compounds were found mitochondriotoxic in our assay. Although further investigations will be needed, these data suggest that for some drugs mitochondrial toxicity could occur via the generation of reactive metabolite(s). It is noteworthy that besides parent drugs, metabolites can be also tested for their mitochondrial liability with our assay provided they can be synthesized in stable forms. Finally, in contrast to CYP-generated reactive metabolites, our screening tests on isolated mitochondria will be unable to detect some mitochondrial alterations requiring repeated and long-term exposure, such as mtDNA depletion ([@CIT0001]; [@CIT0013]; [@CIT0025]). Although this mechanism of mitochondrial toxicity could be uncommon, this issue underscores the need to use other *in vitro* models, such as hepatoma cell lines, whenever long-term toxicity should be investigated.

Mitochondrial toxicity had already been described for numerous hepatotoxic compounds selected in our research program. However, our study allowed disclosing mitochondrial toxicity with some compounds for which such a detrimental effect had not been previously reported. For instance, we showed that lumiracoxib (a NSAID removed from the market for hepatotoxicity) strongly inhibited the oxygen consumption through respiratory chain complexes I and II ([Table 1](#T1){ref-type="table"}, [Fig. 3A](#F3){ref-type="fig"}). We also found that the antiretroviral protease inhibitors nelfinavir, ritonavir, and saquinavir collapsed the ΔΨ~m~ and altered the mitochondrial respiration for concentrations lower than 50μM ([Table 1](#T1){ref-type="table"}). Because the reduced mitochondrial respiration and ΔΨ~m~ have been reported in cells treated with indinavir ([@CIT0018]; [@CIT0046]), our investigations suggest that mitochondrial toxicity could be common to the whole class of protease inhibitors. Moreover, we showed that low concentrations of the tyrosine kinase inhibitors gefitinib, imatinib, nilotinib, and sunitinib reduced the ΔΨ~m~ ([Table 1](#T1){ref-type="table"}), although mitochondrial dysfunction has been reported only for gefitinib and sunitinib ([@CIT0016]; [@CIT0022]; [@CIT0048]). In addition to the three antiretroviral protease inhibitors and the six tyrosine kinase inhibitors that are all hepatotoxic but one (nilotinib), we carried out investigations with other therapeutic classes that included more compounds. For instance, 16 antibiotics and 15 NSAIDs were studied, but only two drugs were not hepatotoxic in each of these classes. Thus, the low number of drugs not inducing DILI in these therapeutic classes precluded any conclusion regarding the performance of our assay for drugs belonging to the same therapeutic class but differing in their potential hepatotoxicity. Much more drugs should be studied in order to address this important issue.

Our study also permitted to clarify the mechanisms of mitochondrial toxicity for a few compounds already known to induce mitochondrial dysfunction. For instance, we established that low concentrations of flufenamic acid and tolfenamic acid inhibited the succinate-driven mitochondrial respiration and lowered the ΔΨ~m~ ([Table 1](#T1){ref-type="table"}). However, although the latter effect is most probably due to OXPHOS uncoupling ([@CIT0019]; [@CIT0028]; [@CIT0032]), inhibition of the respiratory chain has not been described so far with these anti-inflammatory agents. Further investigations will be needed in order to determine whether this novel mechanism plays a major role in flufenamic- and tolfenamic acid-induced hepatotoxicity. We also demonstrated that several paraben derivatives impaired the mitochondrial respiration, especially by inhibiting the glutamate/malate-driven respiration ([Table 1](#T1){ref-type="table"}). Previous investigations have only reported paraben-induced mPTP opening in the presence of Ca^2+^ ([@CIT0033]). Interestingly, paraben-induced liver abnormalities have recently been reported in rodents ([@CIT0047]). Thus, long-term exposure to parabens may cause liver toxicity in human and may represent a major health problem, regarding their widely spread use.

Several parameters were selected in this work in order to assess mitochondrial function because chemicals can be toxic for liver mitochondria by different mechanisms. However, it is currently not possible to tell which parameters could be considered as a primary marker because any significant disturbance of each of the selected parameters could have severe consequences on mitochondrial function and hepatocyte viability. For instance, whereas cytochrome *c* release can induce apoptosis, the loss of transmembrane potential can impair ATP production and lead to necrosis ([@CIT0023]; [@CIT0039]). Moreover, from the current knowledge, it is also impossible to tell whether drugs inducing more than one parameter would induce DILI more frequently. Finally, it is important to underline that the different selected parameters can be interdependent. For instance, drugs impairing oxygen consumption can also disturb the transmembrane potential. Thus, more investigations are required to determine whether one particular mitochondrial parameter is better than the others in order to predict DILI.

In this study, hepatotoxicity was determined using the "Hepatox" database ([@CIT0004]; <http://hepatoweb.com/hepatox.php>), which includes compounds inducing different types of injury, such as cytolysis, cholestasis, and steatosis. Even if numerous investigations showed that mitochondrial dysfunction plays a predominant role in hepatic cytolysis and steatosis ([@CIT0001]; [@CIT0013]; [@CIT0023]; [@CIT0027]; [@CIT0039]; [@CIT0042]), no subclasses were done in this study. Indeed, the limited number of compounds within each DILI subgroup precluded a valid statistical analysis. In contrast, mitochondrial toxicity may not be a major mechanism involved in drug-induced cholestasis, although this issue will deserve further investigations because many bile salt transporters function in an ATP-dependent manner ([@CIT0038]). We plan to study additional compounds to determine whether our screening tests could provide a significant positive predictive value for one or several types of DILI.

In conclusion, our multiparametric assay performed on isolated mouse liver mitochondria may be an interesting tool for screening drug candidates and helpful to select safer compounds for further development. Indeed, our tests for screening drug-induced mitochondrial toxicity can provide rapid and valuable information that can be used to determine the potential ability of drug candidates to induce DILI. Moreover, this multiparametric assay can represent an appealing tool to decipher the mechanisms whereby marketed drugs induce dire side effects related to mitochondrial dysfunction.
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